会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 34. 发明公开
    • 메타미포프(Metamifop)를 유효성분으로 함유하는 상승적 작용성을 지닌 제초제 조성물
    • 包含METAMIFOP的合成除草剂组合物
    • KR1020080014459A
    • 2008-02-14
    • KR1020060076223
    • 2006-08-11
    • 주식회사 팜한농
    • 정봉진김태준권오연김영권강경구유홍재오태현
    • A01N43/76A01P13/00
    • A01N43/76A01N35/06A01N39/02A01N47/36C07C235/24C07D263/54C07D413/12
    • Synergistic herbicidal compositions comprising metamifop are provided to increase herbicidal activity and herbicidal spectrum, reduce the use amount of metamifop, and cut down the weed control costs by adding compounds having different herbicidal properties as compared with metamifop. A herbicidal composition comprises metamifop([R]-2-[4-(6-chloro-2-benzooxazolyloxy)-phenoxy]-propionic acid-N-(2-fluorophenyl)-N-methyl amide) as a basic effective ingredient and at least one other herbicidal material having different function properties or herbicidal properties selected from sulfonylurea compounds, aryloxypropionate & cyclohexanedione compounds, sulfonylurea-resistant compounds, phenoxy compounds and bentazone, wherein the sulfonylurea compound is azimsulfuron, bensulfuron-methyl, metsulfuron or nicosulfuron; the aryloxypropionate & cyclohexanedione compound is clodinafop, fenoxaprop, clethodim or tralkoxydim; the sulfonylurea-resistant compound is benzobicyclon, cafenstrole, carfentrazone, mefenacet or thiobencarb; and phenoxy compound is 2,4-D or MCPA(2-methyl-4-chlorophenoxy acetic acid).
    • 提供包含metamifop的协同除草组合物以增加除草活性和除草频谱,减少metamifop的使用量,并通过添加与metamifop相比具有不同除草性质的化合物来降低杂草控制成本。 除草组合物包含作为碱性有效成分的替米莫司([R] -2- [4-(6-氯-2-苯并恶唑基氧基) - 苯氧基] - 丙酸-N-(2-氟苯基)-N-甲基酰胺) 选自磺酰脲化合物,芳氧基丙酸酯和环己二酮化合物,磺酰脲类化合物,苯氧基化合物和苯达唑的不同功能特性或除草性的至少一种除草材料,其中磺酰脲化合物为叠氮磺嘧磺隆,苄嘧磺隆,甲磺隆或烟嘧磺隆; 芳氧基丙酸酯和环己二酮化合物是clodinafop,fenoxaprop,cuthodim或tralkoxydim; 磺酰脲类化合物是苯并环己酮,咖啡因,氟酮唑酮,甲苯甲酸或硫代苯甲腈; 苯氧基化合物是2,4-D或MCPA(2-甲基-4-氯苯氧基乙酸)。
    • 37. 发明公开
    • 할로겐화된 선택적 안드로겐 수용체 모듈레이터 및 그의사용방법
    • 选择性选择性受体调节剂及其方法
    • KR1020050083771A
    • 2005-08-26
    • KR1020057006606
    • 2003-10-14
    • 유니버시티 오브 테네시 리서치 파운데이션
    • 달톤제임스티.밀러듀안디.인동후아헤얄리스테이너미첼에스.베베르카카렌에이.
    • C07C235/38C07C233/05A61K31/275A61K31/165
    • C07D215/227A61K31/165A61K31/404A61K31/4706A61K31/661C07C235/16C07C235/24C07C255/60C07C335/18C07D209/08C07D271/12
    • This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and/or prevention of acute and/or chronic muscular wasting conditions; e) preventing and/or treating dry eye conditions; f) oral androgen replacement therapy; g) decreasing the incidence of, halting or causing a regression of prostate cancer; and/or h) inducing apoptosis in a cancer cell.
    • 本发明提供一类雄激素受体靶向剂(ARTA)。 这些药剂定义了一种新的化合物亚类,它们是选择性雄激素受体调节剂(SARM)。 已经发现几种SARM化合物对雄激素受体具有非甾类化合物的意想不到的雄激素和合成代谢活性。 已经发现其他SARM化合物对雄激素受体具有非甾类配体的意想不到的抗雄激素活性。 SARM化合物,单独或作为组合物,可用于a)男性避孕; b)治疗各种激素相关病症,例如与老年雄性雄激素降低有关的病症(ADAM),如疲劳,抑郁,性欲降低,性功能障碍,勃起功能障碍,性腺机能减退,骨质疏松症,脱发,贫血, 肥胖,肌营养不良,骨质减少,骨质疏松症,良性前列腺增生,情绪和认知和前列腺癌的改变; c)治疗与男性雄激素降低相关的病症(ADIF),如性功能障碍,性欲降低,性腺机能减退,肌营养不良,骨质减少,骨质疏松症,认知和情绪改变,抑郁症,贫血,脱发,肥胖,子宫内膜异位症,乳腺癌 癌症,子宫癌和卵巢癌; d)治疗和/或预防急性和/或慢性肌肉消瘦病症; e)预防和/或治疗干眼症状; f)口服雄激素替代疗法; g)降低前列腺癌的发生率,停止或导致消退; 和/或h)诱导癌细胞中的细胞凋亡。